

Robert H Vonderheide

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5866535/robert-h-vonderheide-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

18,121
citations

54
h-index

111
g-index

111
ext. papers

22,977
ext. citations

15.1
avg, IF

7.03
L-index

#	Paper	IF	Citations
106	Feasibility and utility of synthetic control arms derived from real-world data to support clinical development.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 528-528	2.2	0
105	Loss and Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100159	3.6	0
104	Systematic illumination of druggable genes in cancer genomes.. <i>Cell Reports</i> , 2022 , 38, 110400	10.6	0
103	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. <i>Cancer Discovery</i> , 2021 , 11, 2014-2031	24.4	16
102	Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3540-3542	12.9	0
101	Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. <i>Nature Communications</i> , 2021 , 12, 3424	17.4	11
100	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. <i>JCO Oncology Practice</i> , 2021 , 17, e1879-e1886	2.3	1
99	Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming. <i>Cancer Immunology Research</i> , 2021 , 9, 877-890	12.5	0
98	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4574-4586	12.9	11
97	Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors 2021 , 9,		3
96	Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. <i>Nature Communications</i> , 2021 , 12, 4365	17.4	9
95	Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. <i>Cancer Discovery</i> , 2021 , 11, 736-753	24.4	17
94	A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 389-397	6.1	3
93	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. <i>Lancet Oncology, The</i> , 2021 , 22, 118-131	21.7	59
92	Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa120	4.6	8
91	Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy. <i>Oncologist</i> , 2021 , 26, 269-273	5.7	9
90	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2497-2505 ³⁴	7.2	34

89	Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. <i>Transplantation and Cellular Therapy</i> , 2021 , 28, 18.e1-18.e1		0
88	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. <i>Oncolimmunology</i> , 2021 , 10, 1863631	7.2	9
87	The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets.. <i>Nature Cancer</i> , 2021 , 2, 1406-1422	15.4	5
86	Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2020 , 11, 605619	8.4	6
85	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. <i>Seminars in Radiation Oncology</i> , 2020 , 30, 173-180	5.5	3
84	Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 8022-8031	11.5	45
83	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3578-3588	12.9	36
82	CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. <i>JCI Insight</i> , 2020 , 5,	9.9	24
81	Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients 2020 ,		4
80	Challenges and Opportunities for Pancreatic Cancer Immunotherapy. <i>Cancer Cell</i> , 2020 , 38, 788-802	24.3	81
79	Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	44
78	Right to Try Requests and Oncologists' Gatekeeping Obligations. <i>Journal of Clinical Oncology</i> , 2020 , 38, 111-114	2.2	4
77	CD40 Agonist Antibodies in Cancer Immunotherapy. <i>Annual Review of Medicine</i> , 2020 , 71, 47-58	17.4	156
76	Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2150-2169	16.6	43
75	Fatty acid transport protein 2 reprograms neutrophils in cancer. <i>Nature</i> , 2019 , 569, 73-78	50.4	215
74	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 4363-4374	12.9	38
73	Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade. <i>Cell Systems</i> , 2019 , 9, 375-382.e4	10.6	36
72	Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients 2019 ,		35

71	Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). <i>Journal of Clinical Investigation</i> , 2019 , 129, 3594-3609	15.9	68
70	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 515-521	4.7	16
69	Understanding the tumor immune microenvironment (TIME) for effective therapy. <i>Nature Medicine</i> , 2018 , 24, 541-550	50.5	1772
68	The Immune Revolution: A Case for Priming, Not Checkpoint. <i>Cancer Cell</i> , 2018 , 33, 563-569	24.3	170
67	Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer. <i>Cancer Immunology Research</i> , 2018 , 6, 276-287	12.5	46
66	Immunotherapy and Prevention of Pancreatic Cancer. <i>Trends in Cancer</i> , 2018 , 4, 418-428	12.5	146
65	Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 594-599	4.7	6
64	Hif1 Δ Deletion Limits Tissue Regeneration via Aberrant B Cell Accumulation in Experimental Pancreatitis. <i>Cell Reports</i> , 2018 , 23, 3457-3464	10.6	3
63	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. <i>Onc Immunology</i> , 2018 , 7, e1468956	7.2	60
62	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. <i>British Journal of Cancer</i> , 2018 , 119, 1200-1207	8.7	59
61	Unique pattern of neutrophil migration and function during tumor progression. <i>Nature Immunology</i> , 2018 , 19, 1236-1247	19.1	77
60	Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. <i>Cancer Research</i> , 2018 , 78, 4282-4291	10.1	63
59	Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. <i>Immunity</i> , 2018 , 49, 178-193.e7	32.3	287
58	Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α 1-antitrypsin deficiency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 1655-1659	11.5	34
57	Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. <i>Blood</i> , 2017 , 129, 906-916	2.2	42
56	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017 , 545, 60-65	50.4	850
55	Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 3129-3138	12.9	127
54	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. <i>Cancer Cell</i> , 2017 , 32, 654-668.e5	24.3	293

53	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2017 , 5, 1152-1161	12.5	181
52	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016 , 7, 12150	17.4	1388
51	CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2016 , 4, 968-982	12.5	129
50	Metastatic progression is associated with dynamic changes in the local microenvironment. <i>Nature Communications</i> , 2016 , 7, 12819	17.4	79
49	CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer. <i>Cell Reports</i> , 2016 , 15, 2719-32	10.6	134
48	Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. <i>Cancer Discovery</i> , 2016 , 6, 256-69	24.4	133
47	Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. <i>JCI Insight</i> , 2016 , 1,	9.9	79
46	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. <i>American Journal of Hematology</i> , 2016 , 91, 453-60	7.1	6
45	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. <i>Cell</i> , 2016 , 167, 1540-1554.e12	56.2	538
44	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunology Research</i> , 2016 , 4, 279-88	12.5	22
43	CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. <i>Journal of Immunology</i> , 2016 , 197, 179-87	5.3	37
42	Special Conference on Tumor Immunology and Immunotherapy: A New Chapter. <i>Cancer Immunology Research</i> , 2015 , 3, 590-597	12.5	13
41	Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. <i>Gastroenterology</i> , 2015 , 149, 201-10	13.3	182
40	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. <i>Cancer Immunology Research</i> , 2015 , 3, 399-411	12.5	289
39	Awakening the immune system with radiation: Optimal dose and fractionation. <i>Cancer Letters</i> , 2015 , 368, 185-90	9.9	68
38	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015 , 520, 373-7	50.4	1509
37	CD47 blockade as another immune checkpoint therapy for cancer. <i>Nature Medicine</i> , 2015 , 21, 1122-3	50.5	67
36	Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2078-83	5.1	3

35	NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. <i>Blood</i> , 2015 , 125, 3655-63	2.2	31
34	Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. <i>Cancer Research</i> , 2015 , 75, 2800-2810	10.1	247
33	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2392-8	2.2	38
32	Mitigating the toxic effects of anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 91-9	19.4	150
31	Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe Kras. <i>Cancer Cell</i> , 2014 , 25, 553-4	24.3	13
30	Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. <i>Cancer Immunology Research</i> , 2014 , 2, 1051-8	12.5	32
29	Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. <i>Cancer Immunology Research</i> , 2014 , 2, 19-26	12.5	58
28	Engineering T cells for cancer: our synthetic future. <i>Immunological Reviews</i> , 2014 , 257, 7-13	11.3	38
27	CD40 immunotherapy for pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 949-54	7.4	77
26	Immunotherapy at large: the road to personalized cancer vaccines. <i>Nature Medicine</i> , 2013 , 19, 1098-100	50.5	41
25	Inflammatory networks and immune surveillance of pancreatic carcinoma. <i>Current Opinion in Immunology</i> , 2013 , 25, 200-5	7.8	134
24	Agonistic CD40 antibodies and cancer therapy. <i>Clinical Cancer Research</i> , 2013 , 19, 1035-43	12.9	300
23	Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. <i>Oncolmmunology</i> , 2013 , 2, e23033	7.2	131
22	A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. <i>Clinical Cancer Research</i> , 2013 , 19, 6286-95	12.9	321
21	CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. <i>Science Translational Medicine</i> , 2012 , 4, 134ra62	17.5	216
20	EMT and dissemination precede pancreatic tumor formation. <i>Cell</i> , 2012 , 148, 349-61	56.2	1422
19	Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. <i>Cancer Cell</i> , 2012 , 21, 822-35	24.3	648
18	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. <i>Science</i> , 2011 , 331, 1612-6	33.3	1177

17	Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. <i>Clinical Cancer Research</i> , 2010 , 16, 3485-94	12.9	212
16	Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. <i>Cancer Biology and Therapy</i> , 2010 , 10, 983-93	4.6	111
15	Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. <i>Journal of Translational Medicine</i> , 2009 , 7, 93	8.5	48
14	Prospects and challenges of building a cancer vaccine targeting telomerase. <i>Biochimie</i> , 2008 , 90, 173-80	4.6	40
13	Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. <i>Cancer Research</i> , 2007 , 67, 10546-55	10.1	79
12	Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. <i>Journal of Clinical Oncology</i> , 2007 , 25, 876-83	2.2	382
11	Prospect of targeting the CD40 pathway for cancer therapy. <i>Clinical Cancer Research</i> , 2007 , 13, 1083-8	12.9	136
10	Dynamics of the immune reaction to pancreatic cancer from inception to invasion. <i>Cancer Research</i> , 2007 , 67, 9518-27	10.1	668
9	Universal tumor antigens for cancer vaccination: targeting telomerase for immunoprevention. <i>Discovery Medicine</i> , 2007 , 7, 103-8	2.5	12
8	Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. <i>Clinical Cancer Research</i> , 2004 , 10, 828-39	12.9	211
7	RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. <i>Blood</i> , 2004 , 103, 2046-54	2.2	117
6	A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. <i>Immunologic Research</i> , 2003 , 27, 341-56	4.3	26
5	Telomerase as a universal tumor-associated antigen for cancer immunotherapy. <i>Oncogene</i> , 2002 , 21, 674-9	9.2	132
4	Phase I study of recombinant human CD40 ligand in cancer patients. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3280-7	2.2	182
3	Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. <i>Nature Medicine</i> , 2000 , 6, 667-72	50.5	155
2	The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. <i>Immunity</i> , 1999 , 10, 673-9	32.3	475
1	Telomerase as a universal tumor-associated antigen for cancer immunotherapy		1